Alpha 2.0
Login Register
» Articles » PMID: 32571606

Amantadine Treatment for People with COVID-19

Overview
Journal Arch Med Res
Specialty General Medicine
Date 2020 Jun 24
PMID 32571606
Citations 29
Authors
Ramiro Araujo
Jose Dolores Aranda-Martinez
Gonzalo Emiliano Aranda-Abreu
Affiliations
Soon will be listed here.
Abstract

SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19.

Citing Articles

A deep drug prediction framework for viral infectious diseases using an optimizer-based ensemble of convolutional neural network: COVID-19 as a case study.

Aruna A, Babu K, Deepthi K Mol Divers. 2024; .

PMID: 39379663 DOI: 10.1007/s11030-024-11003-7.

Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.

Arman M, Alam S, Maruf R, Shams Z, Islam M Narra J. 2024; 4(1):e319.

PMID: 38798846 PMC: 11125382. DOI: 10.52225/narra.v4i1.319.

Drug Nanocrystals: A Delivery Channel for Antiviral Therapies.

Chaturvedi A, Sharma S, Shukla R AAPS PharmSciTech. 2024; 25(3):41.

PMID: 38366178 DOI: 10.1208/s12249-024-02754-5.

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.

van Wamelen D, Leta V, Chaudhuri K, Jenner P Curr Neuropharmacol. 2023; 22(10):1606-1620.

PMID: 37526188 PMC: 11284721. DOI: 10.2174/1570159X21666230731110709.

Illicit COVID-19 products online: A mixed-method approach for identifying and preventing online health risks.

Catalani V, Townshend H, Prilutskaya M, Chilcott R, Metastasio A, Banayoti H PLoS One. 2023; 18(6):e0287231.

PMID: 37327233 PMC: 10275425. DOI: 10.1371/journal.pone.0287231.

References
1.
Aranda Abreu G, Aguilar M, Covarrubias D, Rojas Duran F . Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020; 140:109755. PMC: 7182751. DOI: 10.1016/j.mehy.2020.109755. View
2.
McKimm-Breschkin J, Fry A . Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016; 129:21-38. PMC: 7132401. DOI: 10.1016/j.antiviral.2016.01.012. View
3.
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M . Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(4):e208857. DOI: 10.1001/jamanetworkopen.2020.8857. View
4.
Smieszek S, Przychodzen B, Polymeropoulos M . Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020; 55(6):106004. PMC: 7191300. DOI: 10.1016/j.ijantimicag.2020.106004. View
5.
Molina J, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L . No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020; 50(4):384. PMC: 7195369. DOI: 10.1016/j.medmal.2020.03.006. View